Evidence map›Paper›PMID 26906175›Full record

ArticleBMC cancer2016

Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.

Xiaoli Huang, Björn Borgström, Sebastian Kempengren, Lo Persson, Cecilia Hegardt, Daniel Strand, Stina Oredsson

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaoli HuangDepartment of Biology, Lund University, Lund, Sweden. xiaoli.huang@biol.lu.se.
Björn BorgströmDepartment of Chemistry, Center for Analysis and Synthesis, Lund University, Lund, Sweden. bjorn.borgstrom@chem.lu.se.
Sebastian KempengrenDepartment of Biology, Lund University, Lund, Sweden. sebastian89kempengren@gmail.com.
Lo PerssonDepartment of Experimental Medical Science, Lund University, Lund, Sweden. lo.persson@med.lu.se.
Cecilia HegardtDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University Cancer Center/Medicon Village, Lund, Sweden. cecilia.hegardt@med.lu.se.
Daniel StrandDepartment of Chemistry, Center for Analysis and Synthesis, Lund University, Lund, Sweden. daniel.strand@chem.lu.se.
Stina OredssonDepartment of Biology, Lund University, Lund, Sweden. stina.oredsson@biol.lu.se.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer stem cells (CSCs) have been invoked in resistance, recurrence and metastasis of cancer. Consequently, curative cancer treatments may be contingent on CSC selective approaches. Of particular interest in this respect is the ionophore salinomycin, a natural product shown to be 100-fold more active against CSCs than clinically used paclitaxel. We have previously reported that synthetic salinomycin derivatives display increased activity against breast cancer cell lines. Herein we specifically investigate the CSC selectivity of the most active member in each class of C20-O-acylated analogs as well as a C1-methyl ester analog incapable of charge-neutral metal ion transport.

methodsJIMT-1 breast cancer cells were treated with three C20-O-acylated analogs, the C1-methyl ester of salinomycin, and salinomycin. The effects of treatment on the CSC-related CD44(+)/CD24(-) and the aldehyde dehydrogenase positive (ALDH(+)) populations were determined using flow cytometry. The survival ability of CSCs after treatment was investigated with a colony formation assay under serum free conditions. The effect of the compounds on cell migration was evaluated using wound-healing and Boyden chamber assays. The expression of vimentin, related to mesenchymal traits and expression of E-cadherin and β-catenin, related to the epithelial traits, were investigated using immunofluorescence microscopy.

resultsTreatment with each of the three C20-acylated analogs efficiently decreased the putative CSC population as reflected by reduction of the CD44(+)/CD24(-) and ALDH(+) populations already at a 50 nM concentration. In addition, colony forming efficiency and cell migration were reduced, and the expression of the epithelial markers E-cadherin and β-catenin at the cell surface were increased. In contrast, salinomycin used at the same concentration did not significantly influence the CSC population and the C1-methyl ester was inactive even at a 20 μM concentration.

conclusionsSynthetic structural analogs of salinomycin, previously shown to exhibit increased activity against cancer cells, also exhibited improved activity against CSCs across several assays even at nanomolar concentrations where salinomycin was found inactive. The methyl ester analog of salinomycin, incapable of charge-neutral metal ion transport, did not show activity in CSC assays, lending experimental support to ionophoric stress as the molecular initiating event for the CSC effects of salinomycin and related structures.

Indexed as

beta CateninBreast NeoplasmsCadherinsCell Line, TumorCell MovementCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansIonophoresNeoplastic Stem CellsPolyether PolyketidesPyransVimentinbeta CateninCadherinsIonophoresPolyether PolyketidesPyranssalinomycinVimentin

Identifiers

PMID26906175
PMCPMC4765157
OpenAlexW2282089257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.